Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
TransCode Therapeutics (RNAZ)
NASDAQ:RNAZ
RESEARCH TOOLSreports
TransCode Therapeutics (RNAZ) Stock Price & Analysis
151 Followers
RNAZ Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.47 - $356.32
Previous Close$0.5
Volume408.58K
Average Volume (3M)621.23K
Market Cap
$3.30M
Enterprise Value$361.46K
Total Cash (Recent Filing)$3.60M
Total Debt (Recent Filing)$663.29K
Price to Earnings (P/E)>-0.1
Beta0.47
Next Earnings
May 13, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-472.87
Shares Outstanding5,808,053
10 Day Avg. Volume491,752
30 Day Avg. Volume621,233
Standard Deviation0.29
R-Squared0.00396
Alpha-0.16
Financial Highlights & Ratios
Price to Book (P/B)1.40
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.02
Forecast
1Y Price Target
$3.00Price Target Upside497.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
TransCode Therapeutics News
Ownership Overview
3.60% Insiders
0.06% Mutual Funds
0.00% Other Institutional Investors
96.34% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
RNAZ FAQ
What was TransCode Therapeutics’s price range in the past 12 months?
TransCode Therapeutics lowest stock price was $0.47 and its highest was $356.32 in the past 12 months.
What is TransCode Therapeutics’s market cap?
Currently, no data Available
When is TransCode Therapeutics’s upcoming earnings report date?
TransCode Therapeutics’s upcoming earnings report date is May 13, 2024 which is in 23 days.
How were TransCode Therapeutics’s earnings last quarter?
TransCode Therapeutics released its earnings results on Apr 03, 2024. The company reported -$24.4 earnings per share for the quarter, missing the consensus estimate of -$0.7 by -$23.7.
Is TransCode Therapeutics overvalued?
According to Wall Street analysts TransCode Therapeutics’s price is currently Undervalued.
Does TransCode Therapeutics pay dividends?
TransCode Therapeutics does not currently pay dividends.
What is TransCode Therapeutics’s EPS estimate?
TransCode Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TransCode Therapeutics have?
TransCode Therapeutics has 6,570,063 shares outstanding.
What happened to TransCode Therapeutics’s price movement after its last earnings report?
TransCode Therapeutics reported an EPS of -$24.4 in its last earnings report, missing expectations of -$0.7. Following the earnings report the stock price went down -4.412%.
Which hedge fund is a major shareholder of TransCode Therapeutics?
Currently, no hedge funds are holding shares in RNAZ
---
TransCode Therapeutics Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (497.61% Upside)
$3.00 (497.61% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 5.4%
Last 30 Days ▼ 5.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-99.83%
12-Months-Change
Fundamentals
Return on Equity
-759.85%
Trailing 12-Months
Asset Growth
-31.87%
Trailing 12-Months
Company Description
TransCode Therapeutics
TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others.
---
RNAZ Stock 12 Months Forecast
Average Price Target
$3.00
▲(497.61% Upside)
Technical Analysis
Best Analysts Covering RNAZ
1 Year
1 Year Success Rate
0/9 ratings generated profit
1 Year Average Return
-87.71%
assigned a buy rating 5 days ago
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -87.71% per trade.
---